Articles tagged with Drug Resistance
A team of Duke researchers has discovered a previously unknown molecular network that regulates cell death and contributes to breast cancer drug resistance. The study found that high levels of the protein MDM2 block cell death signals, leading to drug resistance in breast cancer cells treated with lapatinib.
Researchers have identified the molecular mechanisms behind two rare diseases: giant axonal neuropathy and ovarian cancer. In GAN, mutations in gigaxonin disrupt neural protein degradation, leading to neurofilament accumulation. Meanwhile, ATP11B facilitates cisplatin resistance in ovarian cancer cells by mediating platinum export.
A study found that ATP11B expression is correlated with higher tumor grade and cisplatin-resistance in human ovarian cancer samples. Loss of ATP11B restored sensitivity to cisplatin and reduced ovarian tumor growth in mice.
Sanofi launches large-scale production of partially synthetic artemisinin, a breakthrough in synthetic biology. The drug, developed by Professor Jay Keasling's team, aims to provide stable supply and low cost for developing countries.
Researchers identify a unique mechanism by which glioblastoma cells develop resistance to EGFR-targeting drugs by hijacking the signaling of PDGFRβ. Targeting both receptors simultaneously prevents resistance and suppresses tumors in laboratory models.
Researchers identified a new class of anti-malarial compounds, 4-(1 H )-quinolone-3-diarylethers, derived from endochin, which effectively treats malaria in birds. The compounds demonstrated strong activity against Plasmodium falciparum and Plasmodium vivax, the parasites responsible for most human cases of malaria.
Researchers at Oregon Health & Science University have developed a new drug called ELQ-300 that shows great promise in treating and preventing malaria. The drug targets the parasite earlier than existing treatments, making it potentially more effective and requiring fewer doses.
James Mier's research focuses on tumor angiogenesis in renal cell carcinomas and overcoming resistance to VEGF inhibition. He aims to block the dual-survival strategy of kidney cancer using HDM2 inhibitors and VEGF-targeted drugs.
A recent study by the European Association of Urology has shown promising results for a combined vaccine and steroid drug therapy in treating chemotherapy-naive castration-resistant prostate cancer (CRPC). The therapy, which involves multi-peptide vaccination therapy with low-dose dexamethasone, has been shown to significantly improve ...
A Dutch study found that abiraterone can block androgen receptor activation directly, in addition to inhibiting CYP17A1 activity. This suggests a new mechanism of action for treating castration-resistant prostate cancer.
A new paper highlights how political conflict can lead to disrupted treatment, promoting resistance to antiretroviral drugs and treatment failure. The authors call for further research and planning to mitigate the effects of treatment interruption in strife-prone nations with high rates of HIV infection.
A multi-site study led by a Miriam Hospital researcher reveals that treatment-experienced HIV patients can safely achieve viral suppression without incorporating the traditional class of HIV medications into their treatment regimen. This new approach could change treatment guidelines, lessen side effects, and increase adherence rates.
A study published in PLOS Medicine reveals that resistance to first line anti-malarial drugs is increasing on the Thai-Myanmar border, with a significant impact on the migrant population. The authors found that alternative treatments are urgently needed to replace the failing regimen.
New research reveals that antibiotic-resistant Staph bacteria exhibit a seasonal pattern, with community-associated strains more likely to infect children during the summer months. In contrast, healthcare-associated strains are more prevalent among seniors during the winter months.
Researchers discovered a molecular mechanism that makes glioblastoma resistant to mTOR inhibitors, leading to the development of a new treatment approach. The novel combination therapy combines an mTOR inhibitor with low-dose arsenic to reverse resistance and induce tumor cell death.
Researchers found that superbugs like E. coli require a balance between two proteins, RbfA and KsgA, to produce proteins. Disrupting this balance could potentially kill the bacteria without harming humans.
Researchers have developed a new antiviral drug that prevents flu viruses from removing sugars on cell surfaces, blocking infection. The drug is effective against resistant strains and may also protect against future variants.
A new class of influenza drug has been shown to prevent the flu virus from spreading and successfully treat mice with lethal strains. The drug works by attaching itself to the virus's molecular machinery, rendering it useless.
A University of Colorado Cancer Center review found that resistant starch kills pre-cancerous cells and reduces inflammation, promoting the growth of good bugs in the bowel. Consuming resistant starch, found in legumes, green bananas, and starchy products, may also have implications for breast cancer prevention.
Researchers have found that immature malaria parasites are significantly less sensitive to artemisinin-based drugs than mature ones. This discovery may lead to more effective treatments for malaria and a better understanding of how the parasite develops resistance to drugs.
A new centre will focus on lead optimisation for diseases of the developing world, including TB. The centre will create 11 new posts and receive a £6.5 million investment over five years.
TB infection rates are forecasted to surge as antibiotics become less effective against the disease. The lack of progress in combating TB is attributed to increasing drug resistance, reminiscent of the 1930s when dedicated sanitaria and invasive surgery were common treatments.
A gene called NEK2 promotes drug resistance in cancer, leading to faster growth and poorer patient outcomes. The finding may improve diagnostic and prognostic tools for cancer care.
Researchers found that drug-resistant melanoma tumors can be controlled by using an on-again, off-again treatment schedule. This approach may prolong the effectiveness of the drug for people with late-stage disease.
Researchers have discovered a new compound that restores health to mice infected with methicillin-resistant Staphylococcus aureus (MRSA). The compound targets an enzyme essential for bacterial survival and has been shown to be highly active against MRSA in mice.
Researchers at Worcester Polytechnic Institute and UMass have developed a whole plant therapy using Artemisia annua, delivering 40 times more artemisinin to the blood than purified artemisinin. This could significantly lower the cost of treating malaria and expand access to antimalarial therapy.
Researchers have identified a new drug target, 4'-Phosphopantetheinyl Transferase PptT, which is essential for Mycobacterium tuberculosis (Mtb) growth and survival. This discovery offers hope for the development of new TB treatments that can shorten treatment duration and combat drug-resistant strains.
A research team has developed a new whole-plant strategy to combat malarial drug resistance, utilizing Artemisia annua and potentially reducing treatment costs. The approach shows promise in treating malaria with a higher chance of success than current modes, offering a locally grown and processed option for fighting the disease.
The University of Maryland School of Medicine is launching a study on drug-resistant malaria in Myanmar, using new genetic markers to track the spread of artemisinin-resistant malaria. The researchers aim to develop tests to identify and monitor the disease, which has caused significant treatment failures in Southeast Asia.
A study published in Nature Neuroscience found that male rats exposed to cocaine showed resistance to its rewarding effects when given the drug as adults, while their female offspring did not. The researchers believe that this may be due to changes in gene expression triggered by paternal exposure to cocaine.
A recent study found that true aspirin resistance is extremely rare, with no cases identified. However, coated aspirin may lead to a false diagnosis due to delayed absorption and coating effects.
Stephen Alexander, a University of Missouri professor, has been selected as an AAAS Fellow for his distinguished research on the molecular basis of drug resistance using model organisms. His work on glycosylation has provided important insights into cellular development and protein storage.
Researchers have found that dual-agent chemotherapy resistance in ovarian cancer arises from unique genetic changes, distinct from single-agent resistance. This discovery may lead to new strategies for overcoming resistance and improving treatment outcomes.
In a phase I trial, ponatinib showed promising results in treating chronic myeloid leukemia (CML), particularly for patients with the T315I mutation. The drug achieved complete hematologic responses in all 12 patients and major cytogenetic responses in 67% of those with other mutations.
A study identified a biomarker that can predict responses to cancer drugs and offers a way to treat drug-resistant tumors. The researchers discovered that inhibition of MED12, a gene mutated in cancers, causes drug resistance by enhancing signaling through the TGF-beta receptor.
A new targeted drug, regorafenib, has demonstrated its ability to control metastatic gastrointestinal stromal tumor (GIST) in patients who have become resistant to all existing therapies. The treatment improved disease control and survival rates for nearly four months longer than placebo.
A diabetes drug initially used to treat insulin resistance has shown promise in improving cognitive performance in some people with Alzheimer's disease. Researchers found that rosiglitazone enhanced learning and memory while normalizing insulin resistance by reducing the negative influence of Alzheimer's on brain-signaling molecules.
A team from the University of Manchester has identified a molecular biomarker that can predict which breast cancer patients are most likely to respond to tamoxifen treatment. The discovery could lead to more effective treatment options for patients who have not responded to traditional therapies.
The AMFm programme has improved access to affordable ACTs in eight countries, with over 155 million doses subsidised between 2010 and 2011. Market share of artemisinin monotherapies decreased in several countries, and private sector QAACT prices fell by up to 80%.
Researchers at Moffitt Cancer Center investigated a novel combination of danusertib and bosutinib to overcome resistance in BCR-ABL gatekeeper mutation-specific disease. They found the synergy was not due to direct inhibition, but rather through the downstream MAPK signaling cascade and impaired activity of c-MYC gene regulator.
Researchers at Princeton University have developed a synthetic enzyme that stabilizes drug molecules, making them resistant to breakdown by the human liver. This approach could lead to improved existing drugs and easier production of radioactive tracer versions for medical imaging.
Scientists have observed that chloroquine is once again effective in combating malaria parasites, particularly in Senegal and other African countries. This development could lead to more affordable treatment options for millions of people in Africa, with the current treatment costing twice as much as chloroquine.
Researchers discovered polymorphisms in HIV-1 that improve resistance to drugs, even without the medication. This finding has significant implications for treating HIV-1 infection, as it suggests newly infected individuals can be drug-resistant before treatment.
A phase I/II study found that combining dabrafenib and trametinib delayed the development of treatment resistance in melanoma patients. The combination was at least twice as effective as BRAF inhibition alone, with significant delays in resistance emergence.
The Scripps Research Institute has received a $20 million grant to research HIV drug resistance and develop new anti-HIV treatments. The HIVE Center will investigate the structure and function of HIV, including how it responds to drugs used in AIDS therapy.
Researchers will examine cancer cell drug resistance and focus on prevention strategies using breast cancer as a proof-of-concept model. The goal is to minimize the probability of drug-resistant cancer cells emerging, which are a major cause of current cancer treatment failure.
Researchers discovered a HIV mutation that makes certain strains more susceptible to treatment. This knowledge will help doctors improve drug regimens for HIV-infected individuals by targeting the 172K polymorphism.
Researchers have found that an off-patent anti-inflammatory drug, oxyphenbutazone, can kill both replicating and non-replicating drug-resistant tuberculosis in laboratory tests. The effective drug may offer a potential new therapy for the over 500,000 people worldwide whose TB has become resistant to standard drug treatments.
Researchers developed a realistic computer simulation to predict drug effects and identify why some treatments fail. The model factors in precise doses, prescription adherence, and viral replication to help develop better combination therapies.
A new mathematical model developed by Harvard scientists helps predict the likelihood of drug resistance in HIV patients, enabling the design of more effective treatment cocktails. The model uses data from clinical trials to simulate patient responses to varying drug dosages, providing a valuable tool for researchers and clinicians.
Renal denervation significantly and sustainably lowers blood pressure in patients with resistant hypertension, reducing risk of kidney disease and cardiovascular events. The Symplicity HTN-2 trial demonstrates the procedure's effectiveness in achieving substantial blood pressure reductions for up to 18 months.
Research at ESC Congress 2012 found that renal denervation regenerates blood vessels, reducing cardiovascular events. The procedure improves central hemodynamics and arterial stiffness in patients with resistant hypertension, suggesting a potential 'fountain of youth' for blood vessels.
Researchers have discovered a range of protein targets in Bacillus anthracis that could be used to create new drugs, potentially reducing the risk of resistance. The identification of novel targets is crucial in the fight against anthrax and biological weapon threats.
A new technology developed by scientists can authenticate drugs in minutes, helping patients in developing countries receive real treatments instead of counterfeit ones. The device uses mass spectrometry and can distinguish between genuine and fake medications.
Researchers identified a brain signal that can predict which depressed patients will respond to ketamine, a rapid-acting antidepressant. The signal also holds clues to the agent's mechanism of action, which may lead to more personalized treatment.
Scientists at St. Jude Children's Research Hospital have identified a universal enzyme essential for influenza virus replication, paving the way for the development of new antiviral drugs that can effectively treat and prevent drug-resistant strains. The discovery may lead to the creation of drugs that not only target influenza but als...
A team of researchers used computational analysis to identify a new therapeutic strategy for treating drug-resistant breast cancer. The study found that disrupting glucose metabolism is an effective approach, targeting existing drugs like Lapatinib. This discovery may offer improved treatments for breast cancer patients.
A new study assessing HIV drug resistance shows rising rates in some areas of Africa since antiretroviral therapy roll-out. The prevalence of drug resistance has increased significantly, mainly driven by non-nucleoside reverse transcriptase inhibitors (NNRTI) resistance in East and Southern Africa.
The FDA Antiviral Advisory Committee discusses the pros and cons of Truvada approval for pre-exposure prophylaxis (PrEP). Dr. Judith Feinberg votes in favor of approval, citing good outcomes and tolerability, while Dr. Lauren V. Wood expresses concerns about inconsistent evidence, adherence issues, and safety concerns. Primary care phy...
Belgian scientists have developed a simple assay to track 'superparasites', a type of Leishmania parasite that causes deadly visceral leishmaniasis. This breakthrough could help monitor the spread and emergence of these drug-resistant microbes, contributing to better control of the disease.